AD031 Inhibitors
AD031 inhibitors encompass a diverse array of compounds that indirectly influence the activity of the protein AD031 by targeting various signaling pathways and cellular processes to which AD031 is functionally linked. Alsterpaullone, by targeting cyclin-dependent kinases, impedes the cell cycle progression, thereby reducing the signals necessary for AD031 activity associated with cell division. Similarly, the mTOR pathway, known to govern cell growth and proliferation, is inhibited by Rapamycin, which suppresses the signal transduction that would otherwise elevate AD031 function. The PI3K/AKT pathway, a critical mediator of cell survival and metabolism, is interrupted by the actions of both Wortmannin and LY294002, leading to dampened AD031 activity due to a shortfall in survival signaling. Cellular stress responses, often accompanied by inflammation and apoptosis, modulate AD031 activity, and this regulation is disrupted by SB203580 and SP600125, which target the p38 MAP kinase and JNK pathways, respectively.
Further along the signaling cascade, MEK inhibitors like PD98059 and U0126 disrupt the MAPK/ERK pathway,which is vital for cell differentiation and proliferation, consequently decreasing the functional activity of AD031. The inhibition of this pathway results in a direct reduction of the proliferative signals that would otherwise enhance AD031 activity. The Rho-associated kinase (ROCK) pathway, which Y-27632 inhibits, plays a role in cytoskeletal organization; its inhibition likely reduces AD031 activity tied to cytoskeletal rearrangements. Furthermore, ZM 336372's inhibition of Raf kinase leads to diminished MAPK/ERK signaling, further contributing to a reduction in AD031 activity, especially if AD031 is influenced by ERK-mediated signaling events. The targeting of EGFR-associated pathways by Gefitinib disrupts cell survival and proliferative signaling, which could indirectly lead to a decrease in AD031 activity, assuming AD031 is involved in such pathways.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a cyclin-dependent kinase inhibitor that halts the cell cycle. Since AD031's activity is heightened during cell division, the inhibition of cyclin-dependent kinases by Alsterpaullone would reduce the cellular proliferation signals, consequently decreasing AD031 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that suppresses cell growth and proliferation. AD031, being linked to cellular growth pathways, would have reduced activity as the mTOR pathway directly influences cellular growth signals that modulate AD031's function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor. By inhibiting PI3K, it disrupts the PI3K/AKT signaling pathway, a regulator of cell survival and metabolism, which would indirectly lead to decreased AD031 activity due to reduced survival signals. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAP kinase inhibitor, which can inhibit stress-activated protein kinase pathways involved in inflammatory responses. As AD031 may be responsive to inflammatory signals, inhibiting p38 MAP kinase would decrease AD031 activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of phosphatidylinositol 3-kinase, leading to the inhibition of the AKT signaling pathway. This results in reduced cell survival and growth signals, thereby decreasing AD031 activity which is associated with these pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a MEK inhibitor that disrupts the MAPK/ERK pathway, which is involved in cell differentiation and proliferation. Inhibition of this pathway would lead to decreased AD031 activity, as AD031 is likely influenced by ERK-mediated signaling. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is implicated in stress responses and apoptosis. Inhibition of JNK signaling can decrease AD031 activity by reducing pro-apoptotic signals that may regulate AD031. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that blocks the function of Rho-associated, coiled-coil containing protein kinase. This inhibition can reduce cytoskeletal reorganization signals, which could decrease AD031 activity if it is associated with cytoskeletal dynamics. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a selective inhibitor of MEK1/2, leading to the blockade of the MAPK/ERK pathway. Inhibition of this pathway results in reduced cellular proliferation signals, which would lead to decreased AD031 activity if it is proliferation-associated. | ||||||
ZM 336372 | 208260-29-1 | sc-202857 | 1 mg | $47.00 | 2 | |
ZM 336372 is a potent inhibitor of Raf kinase, which is upstream of the MAPK/ERK signaling pathway. By inhibiting Raf kinase, the subsequent decrease in MAPK/ERK signaling would lead to reduced AD031 activity. | ||||||